Clinical efficacy of hyperbaric oxygen combined with idebenone in the treatment of elderly patients with Parkinson's disease

In this study, 100 elderly patients with Parkinson's disease treated in the Department of Neurology of our hospital from December 2022 to December 2024 were selected and divided into study group and control group according to their willingness to treat, with 50 patients in each group. The control group was treated with idebenone, and the study group was treated with hyperbaric oxygen combined with idebenone. The therapeutic effect, inflammatory response, neurological function, cognitive function, and UPDRS scores were compared between the two groups. The total effective rate of the study group was 90. 00%, which was significantly higher than that of the control group (72. 00%) (P < 0.05). Before treatment, the levels of OPN and YKL Y 40 in the two groups were similar (P > 0.05), but decreased after treatment, and the levels in the study group were lower than those in the control group (P < 0.05). Before treatment, the scores of MoCA in the two groups were similar (P > 0.05), and after treatment, the scores of MoCA in the study group were higher than those in the control group (P < 0.05). Before treatment, the UPDRS scores of different grades in the two groups were similar (P > 0.05), but decreased after treatment, and the scores in the study group were lower than those in the control group (P < 0.05). Hyperbaric oxygen combined with idebenone in the treatment of elderly patients with Parkinson's disease has a significant clinical effect, which can improve the inflammatory response and neurological function, and significantly enhance the cognitive ability of patients.